Synonym
SB-203347; SB203347; SB 203347;
IUPAC/Chemical Name
2-(2-((3,5-bis(trifluoromethyl)phenyl)sulfonamido)-4-(trifluoromethyl)phenoxy)benzoic acid
InChi Key
VWKSVPJJPNTCFZ-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H12F9NO5S/c23-20(24,25)11-5-6-18(37-17-4-2-1-3-15(17)19(33)34)16(10-11)32-38(35,36)14-8-12(21(26,27)28)7-13(9-14)22(29,30)31/h1-10,32H,(H,33,34)
SMILES Code
O=C(O)C1=CC=CC=C1OC2=CC=C(C(F)(F)F)C=C2NS(=O)(C3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
573.39
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Marshall LA, Bolognese B, Roshak A. Respective roles of the 14 kDa and 85 kDa phospholipase A2 enzymes in human monocyte eicosanoid formation. Adv Exp Med Biol. 1999;469:215-9. doi: 10.1007/978-1-4615-4793-8_32. PMID: 10667333.
2: Munns MJ, King RG, Rice GE. Contribution of type II PLA2 to prostaglandin formation: a study using a type II PLA2 specific inhibitor SB 203347. Prostaglandins Other Lipid Mediat. 1999 Jul;57(5-6):361-70. doi: 10.1016/s0090-6980(99)00012-x. PMID: 10480490.
3: Surette ME, Dallaire N, Jean N, Picard S, Borgeat P. Mechanisms of the priming effect of lipopolysaccharides on the biosynthesis of leukotriene B4 in chemotactic peptide-stimulated human neutrophils. FASEB J. 1998 Nov;12(14):1521-31. doi: 10.1096/fasebj.12.14.1521. PMID: 9806761.
4: Jackson JR, Bolognese B, Mangar CA, Hubbard WC, Marshall LA, Winkler JD. The role of platelet activating factor and other lipid mediators in inflammatory angiogenesis. Biochim Biophys Acta. 1998 May 20;1392(1):145-52. doi: 10.1016/s0005-2760(98)00012-5. PMID: 9593866.
5: Hundley TR, Marshall LA, Hubbard WC, MacGlashan DW Jr. Characteristics of arachidonic acid generation in human basophils: relationship between the effects of inhibitors of secretory phospholipase A2 activity and leukotriene C4 release. J Pharmacol Exp Ther. 1998 Mar;284(3):847-57. PMID: 9495842.
6: Winkler JD, Bolognese BJ, Roshak AK, Sung CM, Marshall LA. Evidence that 85 kDa phospholipase A2 is not linked to CoA-independent transacylase-mediated production of platelet-activating factor in human monocytes. Biochim Biophys Acta. 1997 Jun 2;1346(2):173-84. doi: 10.1016/s0005-2760(97)00032-5. PMID: 9219900.
7: Tibes U, Friebe WG. Phospholipase A2 inhibitors in development. Expert Opin Investig Drugs. 1997 Mar;6(3):279-98. doi: 10.1517/13543784.6.3.279. PMID: 15989628.
8: Marshall LA, Hall RH, Winkler JD, Badger A, Bolognese B, Roshak A, Flamberg PL, Sung CM, Chabot-Fletcher M, Adams JL, et al. SB 203347, an inhibitor of 14 kDa phospholipase A2, alters human neutrophil arachidonic acid release and metabolism and prolongs survival in murine endotoxin shock. J Pharmacol Exp Ther. 1995 Sep;274(3):1254-62. PMID: 7562496.
